Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | 0.32 | -0.00 | 1.88 |
| FCF Yield | -10.82% | -5.58% | -12.50% | -0.73% |
| EV / EBITDA | -7.33 | -6.36 | -5.42 | -22.80 |
| Quality | ||||
| ROIC | -5.15% | -5.86% | -6.60% | -1.39% |
| Gross Margin | -168.19% | 91.47% | 92.96% | 95.13% |
| Cash Conversion Ratio | 1.40 | 0.56 | 1.12 | 0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.04% | -5.14% | -7.77% | -7.89% |
| Free Cash Flow Growth | -104.40% | 53.69% | -1,553.52% | 86.22% |
| Safety | ||||
| Net Debt / EBITDA | 2.03 | 2.11 | 3.22 | 10.83 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.92 | 2.07 | 1.83 | 1.50 |
| Cash Conversion Cycle | 103.80 | 40.25 | -23.74 | 18.13 |